The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not
been established. Carbapenems are the mainstay of treatment in susceptible isolates …

Acinetobacter baumannii, a non-motile, glucose non fermentative, oxidase negative,
encapsulated, gram-negative coccobacillus, has recently gained importance because of its …

Despite having a reputation of low virulence, Acinetobacter baumannii is an emerging
multidrug-resistant (MDR) pathogen responsible for community-and hospital-acquired …

Acinetobacter baumannii is an opportunistic Gram-negative pathogen with increasing
relevance in a variety of hospital-acquired infections especially among intensive care unit …

Being a multidrug-resistant and an invasive pathogen, Acinetobacter baumannii is one of
the major causes of nosocomial infections in the current healthcare system. It has been …

Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda
Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial …

Antibiotic resistance is one of the biggest challenges for the clinical sector and industry,
environment and societal development. One of the most important pathogens responsible …

During the past few decades Acinetobacter baumannii has evolved from being a commensal
dweller of health-care facilities to constitute one of the most annoying pathogens …

OBJECTIVE: To review and evaluate clinically relevant epidemiology, microbiology, and
clinical studies regarding the treatment of multidrug-resistant Acinetobacter infections. DATA …

Our experience with managing an outbreak of MDR A baumannii in a medical intensive care
unit (ICU) prompted an evidence-based review of the literature, which resulted in few …